Biomedica Immunoassays

4989 €

Contact us!

osteomiR - microRNA Biomarkers

Determination of fracture risk independent of BMD. Simple and standardized miRNA analysis in serum and plasma.

PRODUCT DETAILS

Assay characteristics:

Cat.No.: TW-KT-011-OT
Method:RT-qPCR, relative quantification without standard curve
Kit content:RNA extraction kit, cDNA synthesis and qPCR reagents, primer-coated qPCR plates, software
Kit size:for 48 samples*
Sample type:Serum, plasma (EDTA)
Control:optional: reference serum available on request
Sample size:200 µl serum or plasma required
Incubation time: sample to data in 8 hours with 2 hours hands-on time
Result read-out:The osteomiR™ software uses a proprietary algorithm to convert the individual miRNA data into a single fracture-risk score for the diagnosis of osteoporosis

*): The standardized kit results in a specific osteomiR™ signature. 19 miRNAs will be analysed for each sample resulting in 912 data points in total.

Sensitivity:
LOD: 10 copies/µl (6 replicates, 95% positive detection); LLOQ: 35 copies/µl

Precision:
Intra-assay (n=6) ≤ 20%, Inter-assay (n=3) ≤ 20%

Dilution linearity:
synthetic osteomiRs:
The mean dilution linearity of synthetic controls in human serum samples yields an R² of 0.99 over 6 logs (Cq-range from 20 to 35).

Link to Species cross reactivity


Upon request, customized-assays for complete coverage of rodent or primate osteomiRs can be designed.

Service analysis: we can measure for you. Click link to get your personal customized service quotation.

Back to top

INSTRUCTIONS FOR USE

Click link for:

osteomiR™ IFU, cat# TW-KT-011-OT

miRNA Analytical Service Quotation Form

Back to top

ADDITIONAL INFORMATION

We have identified 19 microRNAs in human serum which
» are associated to bone microstructure and histomorphometry
» are regulated in patients with osteoporotic fractures
» are BMD-independent risk factors for osteoporotic fractures
» regulate bone formation and resorption via multiple pathways
» are novel biomarkers for bone diseases
» can easily be detected in human serum and plasma samples.   

 

Click link for osteomiR™ key publications leading to the identification of these novel biomarker candidates.


Click links for:

TAmiRNA osteomiR™ - Product Folder

TAmiRNA Sample Testing - Service Folder

TAmiRNA osteomiR™ FAQs

TAmiRNA microRNA Services FAQs

 

 

Back to top

REFERENCES, APPLICATIONS

Cost-utility analysis of fracture risk assessment using microRNAs compared with standard tools and no monitoring in the Austrian female population
E. Walter, H. Dellago, J. Grillari, H.P. Dimai, M. Hackl
Bone, Volume 108, 2018, pages 44-54.
PMID: 29269173

Click link for: osteomiR™ key publications

Differentially circulating miRNAs after recent osteoporotic fractures can influence osteogenic differentiation.
Weilner S, Skalicky S, Salzer B, Keider V, Wagner M, Hildner F, Gabriel C, Dovjak P, Pietschmann P, Grillari-Voglauer R, Grillari J, Hackl M.
Bone 2015; 79: 43 –51.
PMID: 26026730

Secreted microvesicular miR-31 inhibits osteogenic differentiation of mesenchymal stem cells.Aging Cell 2016; 1–11.Circulating microRNAs as novel biomarkers for bone diseases–complex signatures for multifactorial diseases?Hackl M, Heilmeier U, Weilner S, Grillari J. Mol Cell Endocrinol 2015; 432: 83-95.Serum microRNAs are indicative of skeletal fractures in postmenopausal women with and without type-2 diabetes and influence osteogenic and adipogenic differentiation of adipose-tissue derived mesenchymal stem cells in vitro.J Bone Miner Res 2016 Jun 27.Circulating microRNA signatures in patients with idiopathic and postmenopausal osteoporosis and fragility fractures. J Clin Endocrinol Metab. 2016 Aug 23.Jing D, Hao J, Shen Y, Li ML, Huang SH, Zhao Z.The role of microRNAs in bone remodeling.Int J Oral Sci 2015:131–43

 

 

 

Back to top